Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients

Transplantation

Volumn 86, Issue 8, 2008, Pages 1060-1067

  Couzi, Lionel ^a,b,c   Thiébaut, Rodolphe ^c,d   Carron, Jean Claude ^a   Moreau, Jean François ^a,b,c   Merville, Pierre ^a,b,c   Taupin, Jean Luc ^a,b,c  

^a HÔPITAL PELLEGRIN   (France)

^b CNRS Bordeaux Segalen University   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSERM   (France)

Author keywords

Calcineurin inhibitors; Cytokine; Cytomegalovirus; Kidney transplantation; Lymphocytes

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; CALCINEURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENETIC TRANSCRIPTION; GRAFT RECIPIENT; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; AREA UNDER THE CURVE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MONITORING; GENETICS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PROMOTER REGION; PROSPECTIVE STUDY; REPRODUCIBILITY; T LYMPHOCYTE; TIME; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; CALCINEURIN; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-2; JURKAT CELLS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TACROLIMUS; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55949102605     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818758e4     Document Type: Article

References (24)

1. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
2. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686.
3. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
4. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339.
5. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997; 100: 1894.
6. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: A systematic review. Transplantation 2007; 83: 1525.
7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med2007; 357:2562.
8. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2: 112.
9. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
10. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
11. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69.
12. Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995; 59: 1400.
13. Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004; 77: 1815.
14. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82:1280.
15. Sommerer C, Giese T, Schmidt J, et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008; 85: 15.
16. Taupin JL, Merville P, McBride T, et al. Functional quantification of cyclosporine A and FK506 in human whole blood by flow cytometry using the green fluorescent protein as an interleukin-2 reporter gene. J Immunol Methods 2001; 256: 77.
17. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
18. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623.
19. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036.
20. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119.
21. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477.
22. Villacres MC, Longmate J, Auge C, et al. Predominant type 1 CMV-specific memory T-helper response in humans: Evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65: 476.
23. EssaS, RaghupathyR, PacsaAS, et al. Th1-type cytokines production is decreased in kidney transplant recipients with active cytomegalovirus infection. J Med Virol 2000; 60: 223.
24. Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encodedinterleukin-10.J Virol 2002; 76:1285.